Skip to content
← Back to this collection

PUBLICATIONS · 22835780

Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Eur J Cancer
Publication date
2012 Dec
First author
Zsíros J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Zsíros J
      type
      Author
    2. name
      Brugières L
      type
      Author
    3. name
      Brock P
      type
      Author
    4. name
      Roebuck D
      type
      Author
    5. name
      Maibach R
      type
      Author
    6. name
      Child M
      type
      Author
    7. name
      Morland B
      type
      Author
    8. name
      Casanova M
      type
      Author
    9. name
      Pariente D
      type
      Author
    10. name
      Paris C
      type
      Author
    11. name
      de Camargo B
      type
      Author
    12. name
      Ronghe M
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Zsíros J
      type
      Author
    2. name
      Brugières L
      type
      Author
    3. name
      Brock P
      type
      Author
    4. name
      Roebuck D
      type
      Author
    5. name
      Maibach R
      type
      Author
    6. name
      Child M
      type
      Author
    7. name
      Morland B
      type
      Author
    8. name
      Casanova M
      type
      Author
    9. name
      Pariente D
      type
      Author
    10. name
      Paris C
      type
      Author
    11. name
      de Camargo B
      type
      Author
    12. name
      Ronghe M
      type
      Author
    bibliography ids
    1. nci-bib-b0adba3cb8cabfdfdef2ff65
    book metadata
    content sha256
    e3e1cc84e198bc054397e72c73b7d186410a3b590b8963088229fe0aede14cf9
    document type
    citation
    dois
    1. 10.1016/j.ejca.2012.06.023
    electronic publication date
    display
    2012 Jul 24
    precision
    day
    year
    2012
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:22835780
    immutable id
    pubmed:22835780@e3e1cc84e198bc054397e72c73b7d186410a3b590b8963088229fe0aede14cf9
    journal
    abbreviation
    Eur J Cancer
    issn electronic
    1879-0852
    issn print
    0959-8049
    issue
    18
    name
    European journal of cancer (Oxford, England : 1990)
    nlm unique id
    9005373
    pages
    3456-64
    volume
    48
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      22835780
      provenance
      batch id
      1e3045de9f47a5ccd566
      provider
      NCBI PubMed ESummary
      record sha256
      10c1b3c5f34d1f51c2ac4a955475aee82d20cb127e768675896c51ba8195146b
      response sha256
      0c42e87ee821aef9d804e2d77dfdba8876f375111db163986dd22ba43a3d6a52
      retrieved at
      2026-09-09T23:46:50.128287+00:00
      publication date
      display
      2012 Dec
      precision
      month
      year
      2012
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Multicenter Study
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/22835780/
      title
      Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).

      Preserved source evidence · Not medical advice